Molecular typing of drug-resistant TB strains in Central Africa
Official title: Molecular Epidemiology, Strains Genotyping of Multi-drug Resistant Tuberculosis Circulating in Central Africa Region
Run by Centre de Recherche Médicale de Lambaréné · NCT07017803 · Data updated 2026-11-12
This study tests the genetic patterns of drug-resistant TB strains in Central Africa to understand transmission and how resistance may affect new treatment regimens.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 9 Years and up |
| Sex | All |
| Enrollment | 460 (estimated) |
| Sponsor | Centre de Recherche Médicale de Lambaréné Academic / other |
| Locations | 8 sites (Lambaréné and 7 other locations) |
| Status | Recruiting |
| Started | February 9, 2026 |
| Main results expected | November 30, 2026 |
| Study ends | December 24, 2026 |
| Registry record updated | October 29, 2026 |
| Trial ID | NCT07017803 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal participants are GeneXpert-positive TB patients aged 8 years or older who can provide sputum and consent to participate.
✕Probably not a fit
Patients whose samples are of poor quality or contamination may not receive direct benefits from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will analyze TB samples from GeneXpert-positive patients to map lineages and mutations linked to drug resistance, including bedaquiline and fluoroquinolones. The work aims to identify transmission chains and lineage influences on outcomes, informing public health responses. The study uses existing data from the TB-EPI and MESTCAR projects, with samples and data shared across studies where allowed. Quality-controlled samples that meet laboratory criteria will be included to ensure reliable genotyping and resistance profiling.
Why it matters
Potential benefit: If successful, the findings could improve understanding of TB spread and resistance patterns, guiding more effective control measures and regimen choices.
How similar studies have gone: Previous work on TB genotyping has helped map transmission and resistance, though this specific regional analysis in Central Africa is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * All GeneXpert positive TB patients and participants who provide written informed consent will be screened for the study. Participants aged above 8 who can provide sputum will also be screened. * Patients enrolled in the tuberculosis epidemiology (TB-EPI) study and eligible for MESTCAR will be enrolled without any additional consent form as the data to be collected for the two studies will be shared and no additional process is needed. Exclusion Criteria: * Samples which do not meet the quality criteria. * Samples not enough to perform all of the laboratory process * Samples contaminated
Where it's running
-
Centre Hospitalier Régional Georges Rawiri
Lambaréné, Gabon Recruiting -
Hôpital Albert Schweitzer
Lambaréné, Gabon Recruiting -
Hôpital de Nkembo
Libreville, Gabon Recruiting -
Centre Hospitalier Régional de Makokou
Makokou, Gabon Recruiting -
Centre de Traitement Ambulatoire (CTA) de Mouila
Mouila, Gabon Recruiting -
Hôpital de Bongolo
Mouila, Gabon Recruiting
Show 2 more locations
-
Centre Hospitalier Régional d'Oyem
Oyem, Gabon Recruiting -
Centre Hospitalier Régional Tchégué
Port-Gentil, Gabon Recruiting
Study contacts
- Study coordinator: Jabar Babatunde Pacome AGBO ACHIMI ABDUL
- Email: pacomeabdul@gmail.com
- Phone: +24177469843
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Oral Sudapyridine for treating rifampicin-resistant pulmonary tuberculosis
This study is testing if a new medication called Sudapyridine can help people with rifampicin-resistant pulmonary tuberculosis get better compared to another treatment called bedaquiline.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.